The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Cellectis reports $101.1 million nine-month loss as gene-editing pivot advances

Nov 13, 2026 00:24 (2h ago)

Verifying

Cellectis reported third-quarter 2026 results and updated its in vivo gene-editing pipeline.
.HEAL-101 achieved up to 70% APOC3 editing and reduced triglycerides by 76% in mice.
Cellectis had $149 million in cash and deposits on September 30, 2026.